ANDA 64134, held by Bausch & Lomb. Dexamethasone; Tobramycin.
As of Nov 21, 2026, ANDA 64134 (Tobramycin and Dexamethasone), held by Bausch & Lomb, was first approved by FDA on Oct 27, 1999, with 9 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Tobramycin and dexamethasone ophthalmic suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 27, 1999 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Tobramycin and Dexamethasone0.1%;0.3% · suspension/drops;ophthalmic | Dexamethasone; Tobramycin | Rx |
| Jul 21, 2023 | Supplement 29Labeling · Standard review | Approved | None posted |
| Jul 21, 2023 | Supplement 25Labeling · Standard review | Approved | None posted |
| Nov 6, 2008 | Supplement 9Labeling | Approved | None posted |
| Feb 5, 2002 | Supplement 7Manufacturing | Approved | None posted |
| Nov 27, 2001 | Supplement 6Manufacturing | Approved | None posted |
| Mar 7, 2001 | Supplement 4Manufacturing | Approved | None posted |
| Aug 21, 2000 | Supplement 2Manufacturing | Approved | None posted |
| Jul 20, 2000 | Supplement 1Manufacturing | Approved | None posted |
| Jun 27, 2000 | Supplement 3Manufacturing | Approved | None posted |
| Oct 27, 1999 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters